Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population
Adaptive therapy provides the ability to personalize patient treatment at the time of treatment based on patient's anatomy and precise position
New study suggests that high-intensity focused ultrasound ablation is effective against prostate cancer with decreased side effects and improved recovery time.
LOS ANGELES, Sept. 8, 2020 — For some prostate cancer patients, radical treatment (surgery or radiation) are treatment standards. However, these…
SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to KN046, a recombinant humanized PD-L1/CTLA-4 bispecific antibody developed by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu…